Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Debt to Equity (2018 - 2022)

Historic Debt to Equity for Theravance Biopharma (TBPH) over the last 5 years, with Q2 2022 value amounting to -$1.13.

  • Theravance Biopharma's Debt to Equity rose 1095.92% to -$1.13 in Q2 2022 from the same period last year, while for Jun 2022 it was -$1.13, marking a year-over-year increase of 1095.92%. This contributed to the annual value of -$1.15 for FY2021, which is 1117.89% up from last year.
  • Latest data reveals that Theravance Biopharma reported Debt to Equity of -$1.13 as of Q2 2022, which was up 1095.92% from -$1.12 recorded in Q1 2022.
  • Over the past 5 years, Theravance Biopharma's Debt to Equity peaked at -$1.02 during Q4 2019, and registered a low of -$4.45 during Q4 2018.
  • Moreover, its 5-year median value for Debt to Equity was -$1.27 (2021), whereas its average is -$1.62.
  • As far as peak fluctuations go, Theravance Biopharma's Debt to Equity surged by 7699.13% in 2019, and later tumbled by 2612.86% in 2020.
  • Quarter analysis of 5 years shows Theravance Biopharma's Debt to Equity stood at -$4.45 in 2018, then surged by 76.99% to -$1.02 in 2019, then decreased by 26.13% to -$1.29 in 2020, then rose by 11.18% to -$1.15 in 2021, then grew by 1.26% to -$1.13 in 2022.
  • Its Debt to Equity stands at -$1.13 for Q2 2022, versus -$1.12 for Q1 2022 and -$1.15 for Q4 2021.